scbmtБИОМЕДИЦИНАJournal Biomed2074-59822713-0428Scientific center of biomedical technologies of Federal Medical and Biological Agencyscbmt-572Research ArticleСтатьиИсследование сравнительной фармакокинетики широко применяемых гиполипидемических препаратов из группы статиновComparative study of the pharmacokinetics widely used lipid-lowering drugs of the statinСивковА.assivkov2010@mail.ruSivkovA. S.noemail@neicon.ruСивковПервый МГМУ им. И.М. Сеченова, Минздравсоцразвития РФ, Москва КонтактанаRussian Federation2012130220201298104Copyright © Сивков А., Sivkov A.S., 20202020Сивков А., Sivkov A.S.Сивков А., Sivkov A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.scbmt.ru/jour/article/view/572

У 54 здоровых испытуемых исследована сравнительная фармакокинетика широко применяемых ги- полипидемических средств из группы статинов. Концентрацию Аторвастатина, активных метаболитов Симвастатина и Ловастатина определяли в плазме крови методом ВЭЖХ с УФ-спектрофотометрическим детектором.

The comparative pharmacokinetics of commonly used lipid-lowering drugs of the statin was studied by 54 healthy persons. Concentration atorvastatin, the active metabolites of simvastatin and lovastatin in plasma by HPLC with UV-spectrophotometric detector were determined.

фармакокинетикагиперлипидемияpharmacokineticshyperlipidemiaReferencesLennernas H., Fager G. Pharmaco-гия. М: Гэотармед. 2008. dynamics and pharmacokinetics of theКукес В.Г. Метаболизм лекарствен- HMG-CoA reductase inhibitors. Clin.ных средств; клинико-фармакологи- Pharmacokinet. 1997. 32: 403-425.ческие аспекты. М.: Рефарм. 2004.Lennernas H., Fager G. Pharmaco-гия. М: Гэотармед. 2008. dynamics and pharmacokinetics of theКукес В.Г. Метаболизм лекарствен- HMG-CoA reductase inhibitors. Clin.ных средств; клинико-фармакологи- Pharmacokinet. 1997. 32: 403-425.ческие аспекты. М.: Рефарм. 2004.Ayanian J.Z., Fuchs C.S., Stone R.M. 9. Long-Term Intervention with Pravas- tatin in Ischemic Disease (LIPID)Lovastatin and rhabdomyolysis. Ann. Study Group. Prevention of cardiovas-Intern. Med. 1988. 109: 682-683. cular events and death with pravastatinCorsini A., Bellosta S., Baetta R. et in patients with coronary heart diseaseal. New insights into the pharmacody- and a broad range of initial cholesterolnamic and pharmacokinetic properties levels. N. ENGL. J. MED. 1998. 339:of statins. Pharmacol. Ther. 1999. 84: 1349-1357.413-428.Ayanian J.Z., Fuchs C.S., Stone R.M. 9. Long-Term Intervention with Pravas- tatin in Ischemic Disease (LIPID)Lovastatin and rhabdomyolysis. Ann. Study Group. Prevention of cardiovas-Intern. Med. 1988. 109: 682-683. cular events and death with pravastatinCorsini A., Bellosta S., Baetta R. et in patients with coronary heart diseaseal. New insights into the pharmacody- and a broad range of initial cholesterolnamic and pharmacokinetic properties levels. N. ENGL. J. MED. 1998. 339:of statins. Pharmacol. Ther. 1999. 84: 1349-1357.413-428.Desager L.P., Horsmans Y. Clinical 10. Muck W. Rational assessment of the in- teraction profile of atorvastatin supportspharmacokinetics of the HMG-CoA its low propensity for drug interactions.reductase inhibitors. Clin. Pharmacoki- Drugs, 1998, 56 (Suppl. 1): 15 - 23.net. 1996. 31: 348-341.Desager L.P., Horsmans Y. Clinical 10. Muck W. Rational assessment of the in- teraction profile of atorvastatin supportspharmacokinetics of the HMG-CoA its low propensity for drug interactions.reductase inhibitors. Clin. Pharmacoki- Drugs, 1998, 56 (Suppl. 1): 15 - 23.net. 1996. 31: 348-341.Hamelin B.A., Turgeon J. Hydrophi- 11. Richter W.O., Jacob B.G., Schwandt P. Interaction between fibre and lovas-licity/lipophilicity: relevance for the 103 Biomedicine № 2, 2012Hamelin B.A., Turgeon J. Hydrophi- 11. Richter W.O., Jacob B.G., Schwandt P. Interaction between fibre and lovas-licity/lipophilicity: relevance for the 103 Biomedicine № 2, 2012А.С. Сивков tatin. Lancet. 1991. 338: 706.А.С. Сивков tatin. Lancet. 1991. 338: 706.Shepherd J., Cobble S.M., Ford J. et al. Prevention of coronary heart disease with pravastatin in men with hypercho- lesterolemia. N. Engl. J. Med. 1995. 333: 1301-1307.Shepherd J., Cobble S.M., Ford J. et al. Prevention of coronary heart disease with pravastatin in men with hypercho- lesterolemia. N. Engl. J. Med. 1995. 333: 1301-1307.Stern R.H., Gibson D.M., Whit- field L.R. Cimetidine does not alter atorvastatin pharmacokinetics or LDL- cholesterol reduction. Eur. J. Clin. Phar- macol. 1998. 53: 475-478.Stern R.H., Gibson D.M., Whit- field L.R. Cimetidine does not alter atorvastatin pharmacokinetics or LDL- cholesterol reduction. Eur. J. Clin. Phar- macol. 1998. 53: 475-478.Wrighton S.A., Vandenbranden M., Ring B.J. The human drug metaboliz- ing cytochromes P450. J. Pharmacoki- net. Biopharm. 1996. 24: 475-489.Wrighton S.A., Vandenbranden M., Ring B.J. The human drug metaboliz- ing cytochromes P450. J. Pharmacoki- net. Biopharm. 1996. 24: 475-489.

The authors declare that there are no conflicts of interest present.